Jill A Macoska1,2, Kristen S Uchtmann2,3, Glen E Leverson3, Kevin T McVary4, William A Ricke2,3. 1. Center for Personalized Cancer Therapy, University of Massachusetts, Boston, Massachusetts. 2. George M. O'Brien Center for Benign Urologic Research, University of Wisconsin, Madison, Wisconsin. 3. Department of Urology, University of Wisconsin, Madison, Wisconsin. 4. Department of Urology, Loyola University Medical Center, Maywood, Illinois.
Abstract
PURPOSE:Medications targeting androgen receptor activity (eg finasteride) or smooth muscle contractility (eg doxazosin) do not resolve lower urinary tract symptoms indicative of lower urinary tract dysfunction in an important subgroup of men. Recently fibrosis has been implicated as another pathobiology contributing to male lower urinary tract symptoms but to our knowledge no systematic studies have been done to assess fibrosis in the context of medical treatment. We determine whether fibrotic changes in the prostate transition zone are associated with an increased risk of clinical progression in participants treated withdoxazosin, finasteride or finasteride plus doxazosin in the MTOPS (Medical Therapy of Prostatic Symptoms) study. MATERIALS AND METHODS:Transition zone biopsy tissues from men who did or did not experience clinical progression onplacebo, doxazosin, finasteride or combination therapy were assessed for collagen content and architectural changes using picrosirius red birefringence and CT-FIRE (Curvelet Transform-Fiber Extraction) analysis. Correlations were made with annotated demographic and clinical data. Statistical analyses were done with the Pearson correlation coefficient, ANOVA and the t-test. RESULTS: High levels of wavy, aligned prostate transition zone collagen significantly correlated with an increased risk of clinical progression among MTOPS trial participants treated withdoxazosin plus finasteride, particularly those with a high body mass index. CONCLUSIONS: Fibrotic changes in the prostate transition zone are associated with an increased risk of clinical progression in men treated with doxazosin plus finasteride. Antifibrotic therapeutics might provide a new treatment approach in men with lower urinary tract dysfunction who do not respond to current medical treatment approaches.
RCT Entities:
PURPOSE: Medications targeting androgen receptor activity (eg finasteride) or smooth muscle contractility (eg doxazosin) do not resolve lower urinary tract symptoms indicative of lower urinary tract dysfunction in an important subgroup of men. Recently fibrosis has been implicated as another pathobiology contributing to male lower urinary tract symptoms but to our knowledge no systematic studies have been done to assess fibrosis in the context of medical treatment. We determine whether fibrotic changes in the prostate transition zone are associated with an increased risk of clinical progression in participants treated with doxazosin, finasteride or finasteride plus doxazosin in the MTOPS (Medical Therapy of Prostatic Symptoms) study. MATERIALS AND METHODS: Transition zone biopsy tissues from men who did or did not experience clinical progression on placebo, doxazosin, finasteride or combination therapy were assessed for collagen content and architectural changes using picrosirius red birefringence and CT-FIRE (Curvelet Transform-Fiber Extraction) analysis. Correlations were made with annotated demographic and clinical data. Statistical analyses were done with the Pearson correlation coefficient, ANOVA and the t-test. RESULTS: High levels of wavy, aligned prostate transition zone collagen significantly correlated with an increased risk of clinical progression among MTOPS trial participants treated with doxazosin plus finasteride, particularly those with a high body mass index. CONCLUSIONS: Fibrotic changes in the prostate transition zone are associated with an increased risk of clinical progression in men treated with doxazosin plus finasteride. Antifibrotic therapeutics might provide a new treatment approach in men with lower urinary tract dysfunction who do not respond to current medical treatment approaches.
Authors: Jinjin Ma; Mehrnaz Gharaee-Kermani; Lakshmi Kunju; John M Hollingsworth; Jeremy Adler; Ellen M Arruda; Jill A Macoska Journal: J Urol Date: 2012-08-17 Impact factor: 7.450
Authors: Karissa B Tilbury; Kirby R Campbell; Kevin W Eliceiri; Sana M Salih; Manish Patankar; Paul J Campagnola Journal: BMC Cancer Date: 2017-02-06 Impact factor: 4.430
Authors: Petra Popovics; Wisam N Awadallah; Sarah E Kohrt; Thomas C Case; Nicole L Miller; Emily A Ricke; Wei Huang; Marisol Ramirez-Solano; Qi Liu; Chad M Vezina; Robert J Matusik; William A Ricke; Magdalena M Grabowska Journal: Prostate Date: 2020-05-01 Impact factor: 4.104
Authors: Hannah Ruetten; Jaskiran Sandhu; Brett Mueller; Peiqing Wang; Helen L Zhang; Kyle A Wegner; Mark Cadena; Simran Sandhu; Lisa L Abler; Jonathan Zhu; Chelsea A O'Driscoll; Britta Chelgren; Zunyi Wang; Tian Shen; Jonathan Barasch; Dale E Bjorling; Chad M Vezina Journal: Am J Physiol Renal Physiol Date: 2020-11-02
Authors: Petra Popovics; Asha Jain; Kegan O Skalitzky; Elise Schroeder; Hannah Ruetten; Mark Cadena; Kristen S Uchtmann; Chad M Vezina; William A Ricke Journal: Int J Mol Sci Date: 2021-11-18 Impact factor: 5.923
Authors: Marta Tenuta; Maria G Tarsitano; Paola Mazzotta; Livia Lucchini; Franz Sesti; Giorgio Fattorini; Carlotta Pozza; Valerio Olivieri; Fabio Naro; Daniele Gianfrilli; Andrea Lenzi; Andrea M Isidori; Riccardo Pofi Journal: Andrology Date: 2020-03-16 Impact factor: 3.842